Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.40 -1.4%	$47.47	$41.61 ▼ $63.33	$97.81B	0.36	12.77 million shs	10.71 million shs
ERGO Entia Biosciences		$0.00	$0.00 ▼ $0.00	N/A	16.65	N/A	N/A
GRI GRI Bio	$1.82 -6.7%	$1.44	$1.10 ▼ $43.69	$4.87M	-1.62	158,905 shs	242,429 shs
SLS SELLAS Life Sciences Group	$1.77 -6.8%	$1.78	$0.77 ▼ $2.27	$189.58M	2.31	1.83 million shs	2.86 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+1.91%	-0.98%	+1.73%	-2.38%	+11.35%
ERGO Entia Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
GRI GRI Bio	-5.80%	+23.42%	+43.38%	+29.14%	-93.37%
SLS SELLAS Life Sciences Group	-1.04%	+0.26%	+21.79%	+46.15%	+72.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.8945 of 5 stars	3.2	3.0	4.2	4.0	3.0	3.3	1.3
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	3.058 of 5 stars	3.5	4.0	0.0	0.0	3.0	0.0	1.3
SLS SELLAS Life Sciences Group	2.1912 of 5 stars	3.5	1.0	0.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.32	Hold	$57.69	21.70% Upside
ERGO Entia Biosciences	0.00	N/A	N/A	N/A
GRI GRI Bio	3.00	Buy	$22.00	1,108.79% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	295.48% Upside

Current Analyst Ratings Breakdown

Latest BMY, GRI, SLS, and ERGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	2.00	$5.92 per share	8.01	$8.08 per share	5.87
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$7.68 per share	N/A
SLS SELLAS Life Sciences Group	$1M	176.61	N/A	N/A	$0.13 per share	13.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.75	7.78	2.43	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
ERGO Entia Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	-$8.21M	-$11.56	N/A	N/A	N/A	N/A	-275.15%	-168.22%	8/12/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest BMY, GRI, SLS, and ERGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	GRI GRI Bio	-$1.31	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.53	N/A	N/A	N/A	$11.32 billion	N/A
5/15/2025	Q1 2025	GRI GRI Bio	-$4.08	-$5.80	-$1.72	-$5.80	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.23%	N/A	92.88%	17 Years
ERGO Entia Biosciences	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Latest BMY, GRI, SLS, and ERGO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.65	1.28	1.17
ERGO Entia Biosciences	N/A	N/A	N/A
GRI GRI Bio	N/A	1.41	1.41
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
ERGO Entia Biosciences	N/A
GRI GRI Bio	33.95%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.09%
ERGO Entia Biosciences	28.30%
GRI GRI Bio	0.13%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
ERGO Entia Biosciences	6	N/A	N/A	Not Optionable
GRI GRI Bio	1	2.50 million	2.49 million	Not Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.38 million	Not Optionable

BMY, GRI, SLS, and ERGO Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00

July 16 at 3:14 PM | marketbeat.com

Sellas Flat on Trial Success

July 16 at 6:14 AM | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16 at 6:14 AM | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What Happened

July 9, 2025 | marketbeat.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.comF

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMY, GRI, SLS, and ERGO Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.40 -0.66 (-1.37%)

Closing price 03:59 PM Eastern

Extended Trading

$47.42 +0.02 (+0.05%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Entia Biosciences OTCMKTS:ERGO

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.

GRI Bio NASDAQ:GRI

$1.82 -0.13 (-6.67%)

As of 03:59 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.77 -0.13 (-6.84%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 +0.00 (+0.28%)

As of 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time